McMaster University has announced the initiation of the AeroVax Phase 2 trial of its ChAd-triCoV/Mac inhaled vaccine against SARS-CoV-2. According to McMaster, the Canadian Institutes of Health Research has provided $8 million to support the study, which will be led by researchers from the university's Michael G. DeGroote Institute for Infectious Disease Research. … [Read more...] about McMaster University initiates the AeroVax Phase 2 trial of its inhaled COVID-19 vaccine
News
Oragenics submits application for Phase 2 trial of ONP-002 intranasal neurosteroid powder for TBI
Oragenics announced that it has submitted an Investigator’s Brochure application to Australian authorities seeking the go-ahead for a Phase 2 trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury. In 2023, Oragenics acquired ONP-002 from Odyssey Health, which had announced Phase 1 results the previous year. In August … [Read more...] about Oragenics submits application for Phase 2 trial of ONP-002 intranasal neurosteroid powder for TBI
Altamira gets US patent covering Bentrio bentonite nasal spray formulation
Altamira Therapeutics said that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent covering the formulation of Bentrio bentonite-based nasal spray. Bentrio received 510(k) clearance in the US in June 2022. In 2023, the company sold a 51% stake in its subsidiary Altamira Medica, which developed Bentrio for the prevention … [Read more...] about Altamira gets US patent covering Bentrio bentonite nasal spray formulation
Tiziana submits IND for Phase 2 trial of intranasal foralumab in ALS
Tiziana Life Sciences announced that it has submitted an IND to the FDA seeking approval for a Phase 2 trial of intranasal foralumab in patients with amyotrophic lateral sclerosis. In November 2024, the company announced that it had received a grant from the ALS Association to fund a trial in patients with ALS. According to the company, the planned Phase 2 study would … [Read more...] about Tiziana submits IND for Phase 2 trial of intranasal foralumab in ALS
Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market
According to DPI developer Iconovo, the company has received a grant worth SEK 670,000 from the EU's Innowwide initiative, which encourages small and medium-sized EU companies to enter international markets. The grant will fund a market study this year that will evaluate opportunities for Iconovo to partner with Japanese companies to sell its products and services in … [Read more...] about Iconovo gets SEK 670,000 Innowwide grant to explore selling its DPIs and services in the Japanese market
ASG says it held pre-IND meeting with FDA regarding Beta 1 PDE-5 inhibitor DPI for erectile dysfunction
Taipei-based inhaled drug developer Asia Scientific Global announced that it has completed a pre-IND meeting with the US FDA regarding its Beta 1 dry powder inhaler, a PDE-5 inhibitor that the company is developing for the treatment of erectile dysfunction. The company said that, "ASG will expedite the revision of clinical trial documents and execute additional test … [Read more...] about ASG says it held pre-IND meeting with FDA regarding Beta 1 PDE-5 inhibitor DPI for erectile dysfunction
Silo Pharma announces additional US patent related to SPC-15 intranasal ketamine
According to Silo Pharma, the US Patent and Trademark Office (USPTO) has indicated that it will issue a new patent on March 4, 2025 that will provide protection for Silo's SPC-15 intranasal ketamine. The company says that the expected patent number for the patent titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females” is … [Read more...] about Silo Pharma announces additional US patent related to SPC-15 intranasal ketamine
Renaissance Lakewood to provide development services for Tiziana’s intranasal foralumab
Tiziana Life Sciences announced that it has contracted with CDMO Renaissance Lakewood for development services related to Tiziana's intranasal foralumab anti-CD3 monoclonal antibody. According to Tiziana, the project includes optimization of the formulation and development of "a comprehensive plan for the scale-up of foralumab in a nasal device." Tiziana is … [Read more...] about Renaissance Lakewood to provide development services for Tiziana’s intranasal foralumab
Boehringer Ingelheim announces initiation of Phase 1/2 trial of BI3720931 inhaled gene therapy for CF
A group comprised of Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium, and CDMO OXB, has announced the initiation of the Phase 1/2 Lenticlair 1 study of BI 3720931, an inhaled lentiviral vector-based gene therapy in adult cystic fibrosis patients who cannot be treated with CFTR modulators. The trial is expected to be completed in 2027. … [Read more...] about Boehringer Ingelheim announces initiation of Phase 1/2 trial of BI3720931 inhaled gene therapy for CF
Zeteo Biomedical launches CygnusMR and Cygnus SDX dry powder nasal delivery devices
Texas-based Zeteo Biomedical has announced the launch of two new devices for intranasal delivery of dry powders: the CygnusMR multi-dose device and the CygnusSDX single dose disposable device. In 2022, the company announced the launch of its ZEOx1 OrionMRQ multi-dose nasal device for delivery of liquid drugs and vaccines. According to Zeteo, the new dry powder nasal … [Read more...] about Zeteo Biomedical launches CygnusMR and Cygnus SDX dry powder nasal delivery devices